NeuroDerm (NDRM) Reports Q1 Loss of $0.25/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NeuroDerm Announces First Quarter 2016 Financial Results
May 26, 2016 7:32 AM EDTREHOVOT, Israel, May 26, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the first quarter ended March 31, 2016.
We are pleased with the recent initiation of our long-term safety trial for ND0612L and ND0612H, and remain on track to achieve our development milestones in 2016 for our lead product candidates, with the ultimate goal of providing a more effective, less invasive treatment option for patients suffering from Parkinsons disease, stated Oded... More
